{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T19:24:43.332002+00:00","company":{"ticker":"SILO","cik":1514183,"company_name":"Silo Pharma, Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"0f87e89ae9d166bc7394bcfa0f3cf022a2973375","cik":1514183,"ticker":"SILO","company_name":"Silo Pharma, Inc.","filed_at":"2026-04-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement","agreement_type":"asset_purchase","counterparty":"Many Ads Inc.","effective_date":"2025-07-29","item_codes_triggered":["1.01"],"value_text":null},"claim":"Silo Pharma, Inc. entered into Agreement with Many Ads Inc. (effective 2025-07-29).","evidence_excerpt":"On July 29, 2025, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Many Ads Inc. (the “Seller”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-039352","anchor_url":"https://secwatch.observer/filing/0001213900-26-039352#claim-0f87e89ae9d166bc7394bcfa0f3cf022a2973375","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390026039352/0001213900-26-039352-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"70d5abccbe601025f63e5736881ed7ca3e1cfaa1","cik":1514183,"ticker":"SILO","company_name":"Silo Pharma, Inc.","filed_at":"2025-12-29T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-06-22","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-06-27","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.","reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Silo Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"June 27, 2025, the Company received a notification\n(the “Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the\nminimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq\nListing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A)\nprovides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business\ndays. The Company init","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-25-125838","anchor_url":"https://secwatch.observer/filing/0001213900-25-125838#claim-70d5abccbe601025f63e5736881ed7ca3e1cfaa1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390025125838/0001213900-25-125838-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"29be25092dc1c7b33c7e140918d6695c8c7d4d65","cik":1514183,"ticker":"SILO","company_name":"Silo Pharma, Inc.","filed_at":"2025-07-03T23:59:59+00:00","payload":{"company_response":"intends to monitor, may consider reverse stock split","compliance_status":"deficient","cure_deadline":"2025-12-24","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 per share","notice_date":"2025-06-27","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":"closing bid price below $1.00 from May 14, 2025 to June 26, 2025","rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Silo Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"June 27, 2025, Silo Pharma, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock\nMarket, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule\n5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain\na minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement\nexists if the deficiency continues for a period of 30 consecutive business days. Based o","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001213900-25-061531","anchor_url":"https://secwatch.observer/filing/0001213900-25-061531#claim-29be25092dc1c7b33c7e140918d6695c8c7d4d65","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1514183/000121390025061531/0001213900-25-061531-index.htm"}]}